TY - JOUR
T1 - Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome
AU - Brierley, Stuart M.
AU - Greenwood-Van Meerveld, Beverley
AU - Sarnelli, Giovanni
AU - Sharkey, Keith A.
AU - Storr, Martin
AU - Tack, Jan
N1 - Funding Information:
The authors are grateful to the National Health and Medical Research Council of Australia (Investigator Leadership Grant, APP2008727, and Development Grant APP2014250 to S.M.B.), the Australian Research Council (Discovery Project, DP180101395 to S.M.B.), Department of Veterans Affairs Senior Research Career Scientist Award (BX003610 to B.V.G.M.), Department of Veterans Affairs (Merit Grant BX002188 to B.G.V.M.), National Institutes of Health (1U01 NS113869 and 1U01NS113871 to S.M.B.; R01 NIDDK119125-01A1 to B.V.G.M.), Oklahoma Center for the Advancement of Science (HR-18-040 to B.V.G.M.), Canadian Institutes of Health Research (FDN148380 to K.A.S.), the University of Leuven (Methusalem Grant to J.T.) and the Fund for Scientific Research Flanders (Research Grants to J.T.) for support of the original research performed in the authors’ laboratories.
Funding Information:
S.M.B. has provided scientific advice and received research grant support from AusHealth, Arena Pharmaceuticals, Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Sosie Heptares. B.V.G.M. has provided scientific advice and assistance to Nocion Therapeutics Inc., Teva Branded Pharmaceuticals Products R & D, Bayer Healthcare, Ironwood Pharmaceuticals, EA Pharma Co. Ltd and Blue Therapeutics. G.S. has provided scientific advice and assistance to Nextbiomics and has served on a Speaker bureau for AlfaSigma, Takeda, Farmagens and Interalia Pharmaceuticals. K.A.S. has provided scientific advice and assistance to Arena Pharmaceuticals and GW Pharmaceuticals and has served on a speaker bureau for Abbvie and received research support from Abalone Inc. M.S. has provided scientific advice and assistance to CaraCare, Bayer AG, Dr. Schwabe, Echo-Pharma, and Medice and has served on a Speaker bureau for Falkfoundation, Microbiotica, Bayer AG, Dr. Schwabe, Medice, Kyowa Kirin, Hexal, and HlH Biopharma. J.T. has provided scientific advice and assistance to Adare, AlfaSigma, Arena, Bayer, Christian Hansen, Clasado, Danone, Devintec, Falk, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neurogastrx, Neutec, Novartis, Nutricia, Ricordati Shionogi, Takeda, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals, has served on a Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Wellspect and Zeria, and has received research support from Biohit, Kiowa Kirin, Shire, Sofar and Takeda Pharmaceuticals.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2023/1
Y1 - 2023/1
N2 - The management of visceral pain in patients with disorders of gut–brain interaction, notably irritable bowel syndrome, presents a considerable clinical challenge, with few available treatment options. Patients are increasingly using cannabis and cannabinoids to control abdominal pain. Cannabis acts on receptors of the endocannabinoid system, an endogenous system of lipid mediators that regulates gastrointestinal function and pain processing pathways in health and disease. The endocannabinoid system represents a logical molecular therapeutic target for the treatment of pain in irritable bowel syndrome. Here, we review the physiological and pathophysiological functions of the endocannabinoid system with a focus on the peripheral and central regulation of gastrointestinal function and visceral nociception. We address the use of cannabinoids in pain management, comparing them to other treatment modalities, including opioids and neuromodulators. Finally, we discuss emerging therapeutic candidates targeting the endocannabinoid system for the treatment of pain in irritable bowel syndrome.
AB - The management of visceral pain in patients with disorders of gut–brain interaction, notably irritable bowel syndrome, presents a considerable clinical challenge, with few available treatment options. Patients are increasingly using cannabis and cannabinoids to control abdominal pain. Cannabis acts on receptors of the endocannabinoid system, an endogenous system of lipid mediators that regulates gastrointestinal function and pain processing pathways in health and disease. The endocannabinoid system represents a logical molecular therapeutic target for the treatment of pain in irritable bowel syndrome. Here, we review the physiological and pathophysiological functions of the endocannabinoid system with a focus on the peripheral and central regulation of gastrointestinal function and visceral nociception. We address the use of cannabinoids in pain management, comparing them to other treatment modalities, including opioids and neuromodulators. Finally, we discuss emerging therapeutic candidates targeting the endocannabinoid system for the treatment of pain in irritable bowel syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85138866630&partnerID=8YFLogxK
U2 - 10.1038/s41575-022-00682-y
DO - 10.1038/s41575-022-00682-y
M3 - Review article
C2 - 36168049
SN - 1759-5045
VL - 20
SP - 5
EP - 25
JO - Nature reviews. Gastroenterology & hepatology
JF - Nature reviews. Gastroenterology & hepatology
IS - 1
ER -